๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

โœ Scribed by Kimberly A. Varker; Jacqueline Campbell; Manisha H. Shah

Publisher
Springer
Year
2007
Tongue
English
Weight
287 KB
Volume
61
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Incidence and morbidity of cholelithiasi
Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors
โœ Michael C. Trendle; Charles G. Moertel; Larry K. Kvols ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 2 views

## Background: Octreotide, a long-acting somatostatin analogue, has demonstrated clinical utility in patients with carcinoid syndrome and malignant islet cell tumors of the pancreas. prior studies have reported a greater than expected incidence of cholelithiasis in patients treated with octreotide

Phase II trial of dimethyltriazenoimidaz
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid
โœ Ronald M. Bukowski; Catherine M. Tangen; Robert F. Peterson; Thomas R. Fleming; ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 347 KB ๐Ÿ‘ 2 views

Background. The use of chemotherapy in patients with metastatic carcinoid tumors has been of limited value, and investigiition of new agents is necessary. Previous reports have suggested that dimethyltriazenoimidazole carboxamide (DTIC) may have antitumor activity. Methods. A Phase I1 trial to inve